Hacker News Reader

Comment by vikramkr | Hacker News Reader

This is amazing - I wish I had this a few weeks ago when I was making a presentation. Does anyone know if images made when on a paid plan would be usable for commercial/publication purposes forever? Or is is only licensed for as long as you have a subscription? I tried to find that on the website but I might just have been missing something obvious, or maybe theres some usual legal standard about how this sort of IP licensing is done by default?

View on HN

It’s in their TOS. The answer is more or less forever:

“Standard Commercial License: A BioRender Standard Commercial License is provided to all paid industry accounts allows you to use our Asset(s) anywhere in the world, and the license never expires.

You may use the Asset(s) in websites, print, presentations, publications, social media sites, marketing and advertising material, broadcasts, and for internal communication. However, you may not share or distribute the Asset(s) in any way that would let others use the Asset(s) without licensing it themselves.”

So we wouldn't be able to photo ship in a diagram into a bigger diagram later and would need to make it not downloadable if we post diagrams on our website? What if someone screenshots it from a journal publication?

If I had to guess, I'd say the intent behind it was "don't produce content which you then license out for re-use by third parties", not "you must make it physically impossible for third parties to re-use the content, even if they're willing to infringe copyright".

>However, you may not share or distribute the Asset(s) in any way that would let others use the Asset(s) without licensing it themselves.”

What does that imply, a watermark on every powerpoint slide?

Not explicitly but in their FAQ: "...upgrade to one of our subscription plans in order to attain publication/commercial rights for your BioRender images." Presumably that means permanent licensing of some kind is included if you pay for the right plan, but need more info.

Reply on news.ycombinator.com